NASDAQ:INBX Inhibrx Biosciences (INBX) Stock Price, News & Analysis $90.61 -1.13 (-1.23%) Closing price 04:00 PM EasternExtended Trading$90.90 +0.28 (+0.31%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Inhibrx Biosciences Stock (NASDAQ:INBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inhibrx Biosciences alerts:Sign Up Key Stats Today's Range$89.99▼$92.9050-Day Range$71.78▼$124.9752-Week Range$57.30▼$155.29Volume100,296 shsAverage Volume310,921 shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$197.50Consensus RatingModerate Buy Company Overview Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines. Inhibrx Biosciences emerged in 2024 from the restructuring of its former parent, Inhibrx, Inc., following Sanofi’s acquisition of certain Inhibrx assets. The company retained a portfolio of development programs, with its work centered on advancing investigational biologics through clinical development.AI Generated. May Contain Errors. Read More Inhibrx Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreINBX MarketRank™: 3.467688648075 of 5 starsInhibrx Biosciences scored higher than 69% of companies evaluated by MarketBeat, and ranked 210th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingInhibrx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialInhibrx Biosciences has a consensus price target of $197.50, representing about 118.0% upside from its current price of $90.61.Amount of Analyst CoverageInhibrx Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Inhibrx Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inhibrx Biosciences are expected to grow in the coming year, from ($9.91) to ($9.34) per share.Price to Book Value per Share RatioInhibrx Biosciences has a P/B Ratio of 164.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inhibrx Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.17% of the float of Inhibrx Biosciences has been sold short.Short Interest Ratio / Days to CoverInhibrx Biosciences has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Inhibrx Biosciences has recently decreased by 0.82%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibrx Biosciences does not currently pay a dividend.Dividend GrowthInhibrx Biosciences does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.35 News SentimentInhibrx Biosciences has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inhibrx Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for INBX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Inhibrx Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership4.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Inhibrx Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $6,178,917.00 in company stock, which represents 0.4633% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Inhibrx Biosciences insiders have bought 3,665.06% more of their company's stock than they have sold. Specifically, they have bought $6,347,507.00 in company stock and sold $168,590.00 in company stock.Percentage Held by Insiders18.26% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inhibrx Biosciences' insider trading history. Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INBX Stock News HeadlinesInhibrx Biosciences (INBX) Expected to Release Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comInhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This PriceOctober 23, 2026 | finance.yahoo.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 10 at 1:00 AM | Weiss Ratings (Ad)Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?October 14, 2026 | finance.yahoo.comInhibrx Announces Participation in Upcoming Scientific ConferencesOctober 13, 2026 | prnewswire.comInhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp ReratingSeptember 29, 2026 | finance.yahoo.comInhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?September 24, 2026 | uk.finance.yahoo.comInhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?September 15, 2026 | fool.comSee More Headlines INBX Stock Analysis - Frequently Asked Questions How have INBX shares performed this year? Inhibrx Biosciences' stock was trading at $79.00 on January 1st, 2026. Since then, INBX stock has increased by 14.7% and is now trading at $90.61. How were Inhibrx Biosciences' earnings last quarter? Inhibrx Biosciences, Inc. (NASDAQ:INBX) released its quarterly earnings results on Thursday, August, 13th. The company reported ($2.34) earnings per share for the quarter, missing analysts' consensus estimates of ($2.28) by $0.06. When did Inhibrx Biosciences IPO? Inhibrx Biosciences (INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx Biosciences' major shareholders? Inhibrx Biosciences' top institutional investors include HighTower Advisors LLC (6.01%), Russell Investments Group Ltd. (0.17%), Profund Advisors LLC (0.03%) and Commonwealth Equity Services LLC (0.03%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Jon Faiz Kayyem, Douglas Forsyth, Global Investors Lp Viking, Kimberly Manhard and Kristiina Md Vuori. View institutional ownership trends. How do I buy shares of Inhibrx Biosciences? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibrx Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include CRISPR Therapeutics (CRSP), CrowdStrike (CRWD), Plug Power (PLUG), Quantum Computing (QUBT), Red Cat (RCAT), Shoals Technologies Group (SHLS) and USA Rare Earth (USAR). Company Calendar Last Earnings8/13/2026Today11/10/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 13 days, INBX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INBX CIK2007919 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees110Year Founded2017Price Target and Rating Average Price Target for Inhibrx Biosciences$197.50 High Price Target$245.00 Low Price Target$150.00 Potential Upside/Downside+118.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($8.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.05 million Net MarginsN/A Pretax Margin-10,014.08% Return on Equity-563.90% Return on Assets-83.48% Debt Debt-to-Equity RatioN/A Current Ratio5.07 Quick Ratio5.07 Sales & Book Value Annual Sales$1.30 million Price / Sales1,025.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book164.75Miscellaneous Outstanding Shares14,720,000Free Float12,030,000Market Cap$1.33 billion OptionableOptionable Beta4.03 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:INBX) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
